{"id":3167,"date":"2018-01-25T17:48:08","date_gmt":"2018-01-25T22:48:08","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/gensight-biologics-publie-e55-million-de-tresorerie-nette-a-fin-2017-et-fait-un-point-sur-son-activite\/"},"modified":"2026-09-24T00:09:50","modified_gmt":"2026-09-24T04:09:50","slug":"gensight-biologics-publie-e55-million-de-tresorerie-nette-a-fin-2017-et-fait-un-point-sur-son-activite","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2018\/01\/25\/gensight-biologics-publie-e55-million-de-tresorerie-nette-a-fin-2017-et-fait-un-point-sur-son-activite\/","title":{"rendered":"GenSight Biologics publie \u20ac55 million de tr\u00e9sorerie nette \u00e0 fin 2017 et fait un point sur son activit\u00e9"},"content":{"rendered":"\n<strong>Paris, France, le 25 janvier \u00a02018, 7h30 CET \u2013<\/strong> GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, publie aujourd\u2019hui sa situation nette de tr\u00e9sorerie au 31 d\u00e9cembre 2017 et fait un point sur son activit\u00e9.\n<h2>Point sur l\u2019activit\u00e9<\/h2>\n<h3>GS010 dans la Neuropathie \u00a0Optique H\u00e9r\u00e9ditaire \u00a0de Leber (NOHL)<\/h3>\n<ul>\n \t<li>Le suivi \u00a0\u00e0 \u00a0long \u00a0terme \u00a0de \u00a0l\u2019\u00e9tude \u00a0de \u00a0Phase \u00a0I\/II \u00a0a \u00a0confirm\u00e9 \u00a0le \u00a0maintien \u00a0des \u00a0r\u00e9sultats pharmacodynamiques prometteurs 2,5 ans apr\u00e8s l\u2019injection chez les patients atteints depuis moins de 2 ans (patients les plus proches des crit\u00e8res d\u2019\u00e9ligibilit\u00e9 des Phases III).<\/li>\n \t<li>Les \u00e9tudes cliniques de Phase III REVERSE et RESCUE ont termin\u00e9 leur recrutement en f\u00e9vrier et juillet 2017, respectivement.<\/li>\n \t<li>Les premiers r\u00e9sultats de REVERSE et RESCUE sont attendus en avril et au 3\u00e8me trimestre 2018, respectivement.<\/li>\n \t<li>L\u2019\u00e9tude clinique bilat\u00e9rale confirmatoire de Phase III REFLECT a \u00e9t\u00e9 initi\u00e9e au 4\u00e8me trimestre 2017. Le premier patient devrait \u00eatre trait\u00e9 au 1er trimestre 2018 aux Etats-Unis.<\/li>\n<\/ul>\n<h3>GS030 dans la R\u00e9tinopathie Pigmentaire (RP)<\/h3>\n<ul>\n \t<li>GS030 a re\u00e7u la designation de M\u00e9dicament Orphelin (ODD) aux Etats-Unis en janvier 2017. Ce statut \u00e9tait d\u00e9j\u00e0 re\u00e7u en Europe.<\/li>\n \t<li>Le MHRA a autoris\u00e9 un CTA au Royaume-Uni pour d\u00e9marrer l\u2019\u00e9tude clinique de Phase I\/II PIONEER, une premi\u00e8re \u00e9tude chez l\u2019homme combinant une th\u00e9rapie g\u00e9nique bas\u00e9e sur l\u2019optog\u00e9n\u00e9tique et un dispositif optronique de stimulation visuelle. Le premier patient devrait \u00eatre trait\u00e9 au 1er trimestre 2018.<\/li>\n<\/ul>\n<h3>Corporate<\/h3>\n<ul>\n \t<li>GenSight a lev\u00e9 \u20ac22,5 millions dans le cadre d\u2019un placement priv\u00e9 en juin 2017.<\/li>\n \t<li>Dr. Barrett Katz a rejoint GenSight au poste de Directeur M\u00e9dical en novembre 2017, venant renforcer l\u2019\u00e9quipe de direction. Il est bas\u00e9 \u00e0 New York, o\u00f9 la Soci\u00e9t\u00e9 a cr\u00e9\u00e9 une filiale am\u00e9ricaine.<\/li>\n \t<li>Julio Benedicto a rejoint GenSight au poste de Vice-Pr\u00e9sident Marketing, pour d\u00e9ployer la strat\u00e9gie de pr\u00e9-commercialisation de GS010.<\/li>\n<\/ul>\n<h2>Situation nette de tr\u00e9sorerie<\/h2>\nLa situation nette de tr\u00e9sorerie de GenSight Biologics s\u2019\u00e9tablissait \u00e0 55,4 millions d\u2019euros au 31 d\u00e9cembre 2017, compar\u00e9e \u00e0 59,5 millions d\u2019euros au 30 septembre 2017.\n<h2>Nombre d\u2019actions composant le capital social<\/h2>\nAu 31 d\u00e9cembre 2017, le nombre d\u2019actions composant le capital social de GenSight Biologics \u00e9tait de 24 234 223 actions ordinaires.\n\nGenSight Biologics publiera ses r\u00e9sultats financiers annuels 2017 le 28 f\u00e9vrier 2018.\n<h2>\u00c0 propos \u00a0de GenSight Biologics<\/h2>\nGenSight Biologics S.A. (GenSight Biologics) est une soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central. Le portefeuille de recherche de GenSight Biologics s\u2019appuie sur deux plates-formes technologiques : le ciblage mitochondrial (Mitochondrial Targeting Sequence, ou MTS) et l\u2019optog\u00e9n\u00e9tique, visant \u00e0 pr\u00e9server ou restaurer la vision chez les patients atteints de maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine. Le candidat m\u00e9dicament le plus avanc\u00e9 de GenSight Biologics, GS010, est en Phase III pour le traitement de la neuropathie optique h\u00e9r\u00e9ditaire de Leber (NOHL), une maladie mitochondriale rare qui conduit \u00e0 une perte irr\u00e9versible de la vue chez les adolescents et les jeunes adultes. En utilisant son approche de th\u00e9rapie g\u00e9nique, les candidats m\u00e9dicaments de GenSight Biologics sont destin\u00e9s \u00e0 offrir aux patients une r\u00e9cup\u00e9ration visuelle fonctionnelle durable apr\u00e8s une seule injection intra-vitr\u00e9enne dans chaque \u0153il.\n","protected":false},"excerpt":{"rendered":"<p>Paris, France, le 25 janvier \u00a02018, 7h30 CET \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, publie aujourd\u2019hui sa situation nette de tr\u00e9sorerie au 31 [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[54],"tags":[],"featured-area":[],"news-topic":[],"news-type":[],"post-year":[],"class_list":["post-3167","post","type-post","status-publish","format-standard","hentry","category-communiques-de-presse-financiers"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GenSight Biologics publie \u20ac55 million de tr\u00e9sorerie nette \u00e0 fin 2017 et fait un point sur son activit\u00e9 - GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2018\/01\/25\/gensight-biologics-publie-e55-million-de-tresorerie-nette-a-fin-2017-et-fait-un-point-sur-son-activite\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenSight Biologics publie \u20ac55 million de tr\u00e9sorerie nette \u00e0 fin 2017 et fait un point sur son activit\u00e9 - GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"Paris, France, le 25 janvier \u00a02018, 7h30 CET \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, publie aujourd\u2019hui sa situation nette de tr\u00e9sorerie au 31 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2018\/01\/25\/gensight-biologics-publie-e55-million-de-tresorerie-nette-a-fin-2017-et-fait-un-point-sur-son-activite\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2018-01-25T22:48:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-24T04:09:50+00:00\" \/>\n<meta name=\"author\" content=\"editeur\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"editeur\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2018\\\/01\\\/25\\\/gensight-biologics-publie-e55-million-de-tresorerie-nette-a-fin-2017-et-fait-un-point-sur-son-activite\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2018\\\/01\\\/25\\\/gensight-biologics-publie-e55-million-de-tresorerie-nette-a-fin-2017-et-fait-un-point-sur-son-activite\\\/\"},\"author\":{\"name\":\"editeur\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a\"},\"headline\":\"GenSight Biologics publie \u20ac55 million de tr\u00e9sorerie nette \u00e0 fin 2017 et fait un point sur son activit\u00e9\",\"datePublished\":\"2018-01-25T22:48:08+00:00\",\"dateModified\":\"2026-09-24T04:09:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2018\\\/01\\\/25\\\/gensight-biologics-publie-e55-million-de-tresorerie-nette-a-fin-2017-et-fait-un-point-sur-son-activite\\\/\"},\"wordCount\":617,\"articleSection\":[\"Communiqu\u00e9 de presse Financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2018\\\/01\\\/25\\\/gensight-biologics-publie-e55-million-de-tresorerie-nette-a-fin-2017-et-fait-un-point-sur-son-activite\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2018\\\/01\\\/25\\\/gensight-biologics-publie-e55-million-de-tresorerie-nette-a-fin-2017-et-fait-un-point-sur-son-activite\\\/\",\"name\":\"GenSight Biologics publie \u20ac55 million de tr\u00e9sorerie nette \u00e0 fin 2017 et fait un point sur son activit\u00e9 - GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2018-01-25T22:48:08+00:00\",\"dateModified\":\"2026-09-24T04:09:50+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2018\\\/01\\\/25\\\/gensight-biologics-publie-e55-million-de-tresorerie-nette-a-fin-2017-et-fait-un-point-sur-son-activite\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2018\\\/01\\\/25\\\/gensight-biologics-publie-e55-million-de-tresorerie-nette-a-fin-2017-et-fait-un-point-sur-son-activite\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2018\\\/01\\\/25\\\/gensight-biologics-publie-e55-million-de-tresorerie-nette-a-fin-2017-et-fait-un-point-sur-son-activite\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenSight Biologics publie \u20ac55 million de tr\u00e9sorerie nette \u00e0 fin 2017 et fait un point sur son activit\u00e9\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a\",\"name\":\"editeur\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g\",\"caption\":\"editeur\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GenSight Biologics publie \u20ac55 million de tr\u00e9sorerie nette \u00e0 fin 2017 et fait un point sur son activit\u00e9 - GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2018\/01\/25\/gensight-biologics-publie-e55-million-de-tresorerie-nette-a-fin-2017-et-fait-un-point-sur-son-activite\/","og_locale":"fr_FR","og_type":"article","og_title":"GenSight Biologics publie \u20ac55 million de tr\u00e9sorerie nette \u00e0 fin 2017 et fait un point sur son activit\u00e9 - GenSight Biologics","og_description":"Paris, France, le 25 janvier \u00a02018, 7h30 CET \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, publie aujourd\u2019hui sa situation nette de tr\u00e9sorerie au 31 [&hellip;]","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2018\/01\/25\/gensight-biologics-publie-e55-million-de-tresorerie-nette-a-fin-2017-et-fait-un-point-sur-son-activite\/","og_site_name":"GenSight Biologics","article_published_time":"2018-01-25T22:48:08+00:00","article_modified_time":"2026-09-24T04:09:50+00:00","author":"editeur","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"editeur","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2018\/01\/25\/gensight-biologics-publie-e55-million-de-tresorerie-nette-a-fin-2017-et-fait-un-point-sur-son-activite\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2018\/01\/25\/gensight-biologics-publie-e55-million-de-tresorerie-nette-a-fin-2017-et-fait-un-point-sur-son-activite\/"},"author":{"name":"editeur","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a"},"headline":"GenSight Biologics publie \u20ac55 million de tr\u00e9sorerie nette \u00e0 fin 2017 et fait un point sur son activit\u00e9","datePublished":"2018-01-25T22:48:08+00:00","dateModified":"2026-09-24T04:09:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2018\/01\/25\/gensight-biologics-publie-e55-million-de-tresorerie-nette-a-fin-2017-et-fait-un-point-sur-son-activite\/"},"wordCount":617,"articleSection":["Communiqu\u00e9 de presse Financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2018\/01\/25\/gensight-biologics-publie-e55-million-de-tresorerie-nette-a-fin-2017-et-fait-un-point-sur-son-activite\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2018\/01\/25\/gensight-biologics-publie-e55-million-de-tresorerie-nette-a-fin-2017-et-fait-un-point-sur-son-activite\/","name":"GenSight Biologics publie \u20ac55 million de tr\u00e9sorerie nette \u00e0 fin 2017 et fait un point sur son activit\u00e9 - GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2018-01-25T22:48:08+00:00","dateModified":"2026-09-24T04:09:50+00:00","author":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a"},"breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2018\/01\/25\/gensight-biologics-publie-e55-million-de-tresorerie-nette-a-fin-2017-et-fait-un-point-sur-son-activite\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2018\/01\/25\/gensight-biologics-publie-e55-million-de-tresorerie-nette-a-fin-2017-et-fait-un-point-sur-son-activite\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2018\/01\/25\/gensight-biologics-publie-e55-million-de-tresorerie-nette-a-fin-2017-et-fait-un-point-sur-son-activite\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"GenSight Biologics publie \u20ac55 million de tr\u00e9sorerie nette \u00e0 fin 2017 et fait un point sur son activit\u00e9"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/8a2d2a33de2f0b0e3dd1f07de6ad0d7a","name":"editeur","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4a00c8c9226d455e2119c2c6af2c29734ebb1664a788cc176e0279f830f34785?s=96&d=mm&r=g","caption":"editeur"}}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3167","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=3167"}],"version-history":[{"count":2,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3167\/revisions"}],"predecessor-version":[{"id":6428,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3167\/revisions\/6428"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=3167"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=3167"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=3167"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=3167"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=3167"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=3167"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=3167"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}